Clinical trial
Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD)…
NCT00037713 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00037713 |
|---|---|
| Title | Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG |
| Official title | The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry EORTC Lung Cancer Cooperative Group Spanish Lung Cancer Group Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung (SAKK) US Department of Veterans… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell Lung |
| Intervention type | Biological |
| Interventions | BEC2 Vaccine |
| Enrollment | 515 |
| Start date | Sep 1, 1998 |
| Primary completion | Oct 1, 2002 |
| Completion | Oct 1, 2002 |
| First posted | May 21, 2002 |
| Last update posted | Apr 8, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: